Keros Therapeutics to receive $20 million Takeda milestone payment for elritercept Phase 3 dosing

• Keros Therapeutics will receive a USD 20 million development milestone payment from Takeda tied to elritercept’s Phase 3 ELRiSE MDS first-patient dosing.
• The milestone falls under the January 16, 2025 global license covering development, manufacturing, commercialization outside mainland China, Hong Kong, Macau.
• Keros expects to distribute 25% of the net cash proceeds from the payment to stockholders.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Keros Therapeutics Inc published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001664710-26-000043), on July 30, 2026, and is solely responsible for the information contained therein.